Lysophosphatidic acid targets vascular and oncogenic pathways via RAGE signaling. Rai V, Touré F, Chitayat S, Pei R, Song F, Li Q, Zhang J, Rosario R, Ramasamy R, Chazin WJ, Schmidt AM (2012) J Exp Med 209: 2339-50 Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility. Mott JD, Khalifah RG, Nagase H, Shield CF, Hudson JK, Hudson BG (1997) Kidney Int 52: 1302-12 Transforming growth factor-beta is involved in the pathogenesis of dialysis-related amyloidosis. Matsuo K, Ikizler TA, Hoover RL, Nakamoto M, Yasunaga C, Pupim LB, Hakim RM (2000) Kidney Int 57: 697-708 Glomerular injury is exacerbated in diabetic integrin alpha1-null mice. Zent R, Yan X, Su Y, Hudson BG, Borza DB, Moeckel GW, Qi Z, Sado Y, Breyer MD, Voziyan P, Pozzi A (2006) Kidney Int 70: 460-70 Clinical Relevance of Biomarkers of Oxidative Stress. Frijhoff J, Winyard PG, Zarkovic N, Davies SS, Stocker R, Cheng D, Knight AR, Taylor EL, Oettrich J, Ruskovska T, Gasparovic AC, Cuadrado A, Weber D, Poulsen HE, Grune T, Schmidt HH, Ghezzi P (2015) Antioxid Redox Signal 23: 1144-70 Isolevuglandin-type lipid aldehydes induce the inflammatory response of macrophages by modifying phosphatidylethanolamines and activating the receptor for advanced glycation endproducts. Guo L, Chen Z, Amarnath V, Yancey PG, Van Lenten BJ, Savage JR, Fazio S, Linton MF, Davies SS (2015) Antioxid Redox Signal 22: 1633-45 Structural basis for ligand recognition and activation of RAGE. Koch M, Chitayat S, Dattilo BM, Schiefner A, Diez J, Chazin WJ, Fritz G (2010) Structure 18: 1342-52 Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage. Voziyan PA, Hudson BG (2005) Cell Mol Life Sci 62: 1671-81 Stable RAGE-heparan sulfate complexes are essential for signal transduction. Xu D, Young JH, Krahn JM, Song D, Corbett KD, Chazin WJ, Pedersen LC, Esko JD (2013) ACS Chem Biol 8: 1611-20 Propagation of protein glycation damage involves modification of tryptophan residues via reactive oxygen species: inhibition by pyridoxamine. Chetyrkin SV, Mathis ME, Ham AJ, Hachey DL, Hudson BG, Voziyan PA (2008) Free Radic Biol Med 44: 1276-85 In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). Novel inhibition of post-Amadori glycation pathways. Booth AA, Khalifah RG, Todd P, Hudson BG (1997) J Biol Chem 272: 5430-7 A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. Voziyan PA, Metz TO, Baynes JW, Hudson BG (2002) J Biol Chem 277: 3397-403 Modification of proteins in vitro by physiological levels of glucose: pyridoxamine inhibits conversion of Amadori intermediate to advanced glycation end-products through binding of redox metal ions. Voziyan PA, Khalifah RG, Thibaudeau C, Yildiz A, Jacob J, Serianni AS, Hudson BG (2003) J Biol Chem 278: 46616-24 S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. Ghavami S, Rashedi I, Dattilo BM, Eshraghi M, Chazin WJ, Hashemi M, Wesselborg S, Kerkhoff C, Los M (2008) J Leukoc Biol 83: 1484-92 Pyridoxamine: the many virtues of a maillard reaction inhibitor. Voziyan PA, Hudson BG (2005) Ann N Y Acad Sci 1043: 807-16 Carbonyl toxicology and Alzheimer's disease. Picklo MJ, Montine TJ, Amarnath V, Neely MD (2002) Toxicol Appl Pharmacol 184: 187-97 α-Lipoic acid antioxidant treatment limits glaucoma-related retinal ganglion cell death and dysfunction. Inman DM, Lambert WS, Calkins DJ, Horner PJ (2013) PLoS One 8: e65389 Chronic aminoguanidine attenuates renal dysfunction and injury in aging rats. Reckelhoff JF, Hennington BS, Kanji V, Racusen LC, Schmidt AM, Yan SD, Morrow J, Roberts LJ, Salahudeen AK (1999) Am J Hypertens 12: 492-8 Procoagulant alveolar microparticles in the lungs of patients with acute respiratory distress syndrome. Bastarache JA, Fremont RD, Kropski JA, Bossert FR, Ware LB (2009) Am J Physiol Lung Cell Mol Physiol 297: L1035-41 Kinetics of nonenzymatic glycation of ribonuclease A leading to advanced glycation end products. Paradoxical inhibition by ribose leads to facile isolation of protein intermediate for rapid post-Amadori studies. Khalifah RG, Todd P, Booth AA, Yang SX, Mott JD, Hudson BG (1996) Biochemistry 35: 4645-54 The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units. Dattilo BM, Fritz G, Leclerc E, Kooi CW, Heizmann CW, Chazin WJ (2007) Biochemistry 46: 6957-70 Regulation of matrix synthesis, remodeling and accumulation in glomerulosclerosis. Pozzi A, Voziyan PA, Hudson BG, Zent R (2009) Curr Pharm Des 15: 1318-33 Site-specific AGE modifications in the extracellular matrix: a role for glyoxal in protein damage in diabetes. Voziyan P, Brown KL, Chetyrkin S, Hudson B (2014) Clin Chem Lab Med 52: 39-45 Significant variation of immunohistochemical marker expression in paired primary and metastatic clear cell renal cell carcinomas. Pan Z, Grizzle W, Hameed O (2013) Am J Clin Pathol 140: 410-8 Alveolar fluid clearance is faster in women with acute lung injury compared to men. Bastarache JA, Ong T, Matthay MA, Ware LB (2011) J Crit Care 26: 249-56 Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine. Booth AA, Khalifah RG, Hudson BG (1996) Biochem Biophys Res Commun 220: 113-9 Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Khalifah RG, Baynes JW, Hudson BG (1999) Biochem Biophys Res Commun 257: 251-8 Ascorbate reverses high glucose- and RAGE-induced leak of the endothelial permeability barrier. Meredith ME, Qu ZC, May JM (2014) Biochem Biophys Res Commun 445: 30-5 Acute lung injury in patients with traumatic injuries: utility of a panel of biomarkers for diagnosis and pathogenesis. Fremont RD, Koyama T, Calfee CS, Wu W, Dossett LA, Bossert FR, Mitchell D, Wickersham N, Bernard GR, Matthay MA, May AK, Ware LB (2010) J Trauma 68: 1121-7 Unusual susceptibility of heme proteins to damage by glucose during non-enzymatic glycation. Cussimanio BL, Booth AA, Todd P, Hudson BG, Khalifah RG (2003) Biophys Chem 105: 743-55 Genetic analysis of advanced glycation end products in the DHS MIND study. Adams JN, Raffield LM, Martelle SE, Freedman BI, Langefeld CD, Carr JJ, Cox AJ, Bowden DW (2016) Gene 584: 173-9 Analysis of advanced glycation end products in the DHS Mind Study. Adams JN, Martelle SE, Raffield LM, Freedman BI, Langefeld CD, Hsu FC, Maldjian JA, Williamson JD, Hugenschmidt CE, Carr JJ, Cox AJ, Bowden DW (2016) J Diabetes Complications 30: 262-8
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.